Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546599 | 0.86 | NPC1 (0.58) | MAPTFAAHTP53TSHRALDH1A1 | |
| SCHEMBL5535039 | 0.84 | ACHE (0.66) | SMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL28869329 | 0.84 | MAPT (1.00) | MAPTSMN1; SMN2FAAHBLMKMT2A | |
| SCHEMBL5542346 | 0.83 | FAAH (0.59) | MAPTSMN1; SMN2FAAHTP53CCR2 | |
| SCHEMBL5536458 | 0.83 | KMT2A (0.58) | MAPTSMN1; SMN2FAAHKMT2AALDH1A1 | |
| SCHEMBL20236190 | 0.83 | MAPT (0.80) | MAPTSMN1; SMN2FAAHBLMKMT2A | |
| SCHEMBL5541740 | 0.83 | FAAH (0.65) | MAPTFAAH | |
| SCHEMBL5546036 | 0.82 | MAPT (0.70) | MAPTSMN1; SMN2FAAHBLMKMT2A | |
| SCHEMBL3949152 | 0.81 | MAPT (0.88) | MAPTSMN1; SMN2FAAHBLMKMT2A | |
| SCHEMBL28860085 | 0.81 | MAPT (0.76) | MAPTSMN1; SMN2FAAHBLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAPT 4117/4885SMN1; SMN2 3985/4885FAAH 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.